Abstract
Objective
The identification of fetal growth disorders is an important clinical priority given that they increase the risk of perinatal morbidity and mortality as well as long-term diseases. A subset of small-for-gestational-age (SGA) infants are growth-restricted, and this condition is often attributed to placental insufficiency. Syndecan-1, a product of the degradation of the endothelial glycocalyx, has been proposed as a biomarker of endothelial damage in different pathologies. During pregnancy, a “specialized” form of the glycocalyx—the “syncytiotrophoblast glycocalyx”—covers the placental villi. The purpose of this study was to determine whether the concentration of maternal plasma syndecan-1 can be proposed as a biomarker for fetal growth restriction.
Study design
A cross-sectional study was designed to include women with normal pregnancy (n = 130) and pregnant women who delivered an SGA neonate (n = 50). Doppler velocimetry of the uterine and umbilical arteries was performed in women with an SGA fetus at the time of diagnosis. Venipuncture was performed within 48 h of Doppler velocimetry and plasma concentrations of syndecan-1 were determined by a specific and sensitive immunoassay.
Results
(1) Plasma syndecan-1 concentration followed a nonlinear increase with gestational age in uncomplicated pregnancies (R2 = 0.27, p < .001); (2) women with a pregnancy complicated with an SGA fetus had a significantly lower mean plasma concentration of syndecan-1 than those with an appropriate-for-gestational-age fetus (p = .0001); (3) this difference can be attributed to fetal growth restriction, as the mean plasma syndecan-1 concentration was significantly lower only in the group of women with an SGA fetus who had abnormal umbilical and uterine artery Doppler velocimetry compared to controls (p = .00071; adjusted p = .0028). A trend toward lower syndecan-1 concentrations was also noted for SGA with abnormal uterine but normal umbilical artery Doppler velocimetry (p = .0505; adjusted p = .067); 4) among women with an SGA fetus, those with abnormal umbilical and uterine artery Doppler findings had a lower mean plasma syndecan-1 concentration than women with normal Doppler velocimetry (p = .02; adjusted p = .04); 5) an inverse relationship was found between the maternal plasma syndecan-1 concentration and the umbilical artery pulsatility index (r = −0.5; p = .003); and 6) a plasma syndecan-1 concentration ≤ 850 ng/mL had a positive likelihood ratio of 4.4 and a negative likelihood ratio of 0.24 for the identification of a mother with an SGA fetus who had abnormal umbilical artery Doppler velocimetry (area under the ROC curve 0.83; p < .001).
Conclusion
Low maternal plasma syndecan-1 may reflect placental diseases and this protein could be a biomarker for fetal growth restriction. However, as a sole biomarker for this condition, its accuracy is low.
Introduction
Fetal growth restriction (FGR) is a risk factor for perinatal morbidity and mortality [Citation1–6] as well as for long-term disorders later in life [Citation7–12]. This condition is suspected when an estimated fetal weight is below the 10th percentile or when there is a deceleration in fetal growth in serial biometry [Citation4,Citation13–18]. The differential diagnosis of small-for-gestational-age (SGA) fetuses includes growth-restricted and constitutionally small fetuses [Citation1,Citation3,Citation19–21]. The combination of an estimated fetal weight below the 10th percentile and abnormal umbilical or uterine Doppler velocimetry is considered indicative of FGR [Citation22–29].
The glycocalyx, a multifunctional surface layer of glycans, covers the surface of epithelial and other types of cells [Citation30]. A specialized glycocalyx lines the endothelium where it acts as a mechanosensory receptor; contributes to the regulation of vascular permeability and the maintenance of anticoagulation; and regulates the interaction between circulating blood cells and the endothelium itself [Citation31–35]. In addition, the glycocalyx can sequester cytokines, angiogenic factors, and enzymes; therefore, it modulates their effects [Citation31,Citation36,Citation37]. In pregnancy, there is a unique glycocalyx—the “syncytiotrophoblast glycocalyx”—that covers the villous tree of the placenta, which is thought to have an important role in the maintenance of blood fluidity in the intervillous space and in the cell-to-cell interaction between maternal white blood cells and the syncytiotrophoblasts [Citation38–42].
Syndecan-1, a transmembrane heparan sulfate proteoglycan, is one of the most studied components of the glycocalyx [Citation43,Citation44]. Extracellular domains of syndecan-1 are constitutively shed, typically via processes regulated by sheddases [Citation35,Citation45–48], and the damage of the endothelial glycocalyx can be assessed by measuring plasma concentrations of this proteoglycan [Citation49,Citation50]. Indeed, plasma syndecan-1 concentrations have been reported to be elevated in several pathologic conditions, e.g. trauma [Citation51,Citation52], sepsis [Citation53–56], renal disease [Citation57,Citation58], heart failure [Citation59], acute coronary syndrome [Citation60], and cerebral ischemia [Citation61]. Syndecan-1 has its predominant expression in the placenta among all human tissues [Citation62]. It is highly expressed in the glycocalyx, covering the chorionic villi of the human placenta [Citation38,Citation39,Citation41,Citation63], where it plays an important anticoagulant role and is involved in the regulation of cell functions in physiologic pregnancies [Citation40,Citation41,Citation64–66]. Previous studies examined the potential value of maternal plasma syndecan-1 as a biomarker for adverse pregnancy outcomes [Citation67]. Recently, Tong et al. reported that mothers with an SGA neonate have a lower median plasma concentration of syndecan-1 than controls [Citation68,Citation69].
The current study was conducted to determine whether pregnant women with an SGA fetus have a difference in the concentration of plasma syndecan-1 as a function of umbilical and uterine artery Doppler velocimetry. We performed a cross-sectional study of pregnancies with an SGA fetus, with and without umbilical and uterine artery Doppler abnormalities, and measured the maternal plasma concentrations of syndecan-1. We tested the hypothesis that maternal plasma syndecan-1 changes when mothers have an SGA fetus with evidence of placental disease reflected by abnormal umbilical artery Doppler velocimetry.
Methods
A retrospective cross-sectional study was conducted by searching the clinical database and bank of biological specimens of the Perinatology Research Branch, NICHD/NIH/DHHS. All patients were enrolled at Hutzel Women’s Hospital at the Detroit Medical Center (Detroit, Michigan, USA) between March 2000 and December 2002. This study included pregnant women between 20 weeks and 42 weeks of gestation who were allocated to the following groups: women with an uncomplicated pregnancy and appropriate-for-gestational-age (AGA) fetus (n = 130) and women diagnosed to have an SGA fetus (n = 50). Exclusion criteria included known fetal chromosomal or major structural anomalies, multiple gestation, and delivery at an outside institution.
Clinical definitions
A patient was considered to have an uncomplicated pregnancy if the following criteria were met: (1) no major medical, obstetrical, or surgical complications, (2) absence of labor at the time of venipuncture, and (3) delivery of a term (≥37 weeks) infant whose birth weight was between the 10th and 90th percentiles for gestational age. The diagnosis of SGA was based on an ultrasonographic estimated fetal weight (EFW) below the 10th percentile according to the Hadlock 4 estimated fetal weight nomogram [Citation70] and confirmed by a birth weight below the 10th percentile for gestational age, according to the reference range proposed by Alexander et al. [Citation71]. Preeclampsia was defined in the presence of hypertension (systolic blood pressure ≥140 mmHg or diastolic blood pressure ≥90 mmHg on at least two occasions, 4 h to 1 week apart, after the 20th week of gestation) and proteinuria (≥ 300 mg in a 24-h urine collection or one dipstick measurement ≥1+) [Citation72].
All women provided written informed consent prior to the collection of plasma samples. The collection of samples and their utilization for research purposes were approved by the Institutional Review Boards of Wayne State University and the NICHD. Many of these samples were previously used in studies of intravascular inflammation, soluble adhesion molecules, and cytokine biology in normal and complicated pregnancies.
Doppler velocimetry of the umbilical and uterine arteries
Color and pulse-wave Doppler ultrasound examinations of the umbilical and uterine arteries were performed by trained personnel in a subset of patients (41 and 40 patients, respectively) at the time of diagnosis of an SGA fetus. The umbilical artery pulsatility index (PI) was measured in a free loop of the umbilical cord. Measurements were taken during periods of fetal inactivity and apnea, with the angle of insonation close to zero. Umbilical artery Doppler velocimetry was defined as abnormal if either the PI was above the 95th percentile for gestational age, or if waveforms were abnormal (absent or reversed end-diastolic velocities) [Citation73,Citation74]. The maternal uterine artery Doppler resistance index (RI) was calculated after sampling the uterine artery within one centimeter of its crossing with the external iliac artery. Measurements were taken bilaterally in duplicate and the average of means of the two sides was the final mean RI. Uterine artery Doppler velocimetry was defined as abnormal if the mean RI (average of right and left) was above the 95th percentile for gestational age and/or if waveform notching was present [Citation75].
Sample collection and human syndecan-1 immunoassay
Blood was collected through venipuncture in ethylenediamine-tetra-acetic acid (EDTA) tubes within 48 h of the diagnosis of SGA and Doppler velocimetry examinations or at a prenatal visit for women in the control group. Plasma was obtained by centrifuging blood at 1300 g for 10 min at 4 °C and then stored at −70 °C. Concentrations of soluble syndecan-1 were determined by a commercially available human syndecan-1 enzyme-linked immunoassay (ELISA) Kit (Cell Sciences, Canton, MA, USA). The sensitivity of the assay was <2.56 ng/mL, and the coefficients of intra-assay variation and inter-assay variation were 7.6% and 6.8%, respectively.
Statistical analysis
After log (base 2) transformation, syndecan-1 concentration data in normal pregnancy were fit by using a quadratic function of gestational age at venipuncture. Differences between SGA subgroups and controls were assessed using a linear model that included the patient group and linear and quadratic terms of gestational age at sampling. Nulliparity was also considered as a covariate but not retained in the final model. P-values for differences between subgroups and the normal pregnancy group were adjusted for multiple comparisons by using the false discovery rate method to obtain q-values, and the false discovery rate was controlled at the 5% level. Syndecan-1 data in cases and controls were displayed in violin plots and summarized as geometric mean and 95% confidence intervals (CI). Chi-square tests were utilized to compare proportions. The relationship between the plasma syndecan-1 concentration and the umbilical or uterine artery Doppler velocimetry was examined by Spearman’s rank correlation tests. A Receiver Operating Characteristic (ROC) curve was generated to assess the diagnostic performance of plasma syndecan-1 concentration for the identification of patients with abnormal umbilical artery Doppler velocimetry. Data were analyzed by using the statistical language and environment version R 3.6.1 and the IBM SPSS version 19.0 (IBM Corporation., Armonk, NY).
Results
Clinical characteristics of the study population
The clinical and demographic characteristics of the study population are displayed in . Eighty percent (40/50) of patients with an SGA fetus delivered a neonate whose birth weight was below the 5th percentile for gestational age. Women with an SGA neonate were more often nulliparous than those with an uncomplicated pregnancy (52% vs. 27%; p = .001). There were no significant differences in the median gestational age at venipuncture, maternal age, and frequency of tobacco and illicit drug usage between the two groups (all, p > 0.05). As expected, patients with SGA had a lower median gestational age at delivery (35.7 weeks vs. 39.5 weeks; p < .001) and a higher rate of preexisting medical diseases (15% vs. 0%; p = .001) than women in the control group (). A total of seven patients presented preexisting medical conditions: four, essential hypertension; one, diabetes mellitus; one, chronic hypertension with diabetes mellitus; and one, chronic hypertension with left nonfunctioning kidney. Four of these patients had abnormal umbilical artery Doppler velocimetry and three had abnormal uterine artery Doppler velocimetry. None of the patients in the SGA group met the criteria to diagnose preeclampsia at the time of diagnosis of SGA. However, one patient developed preeclampsia 10 days later, prior to delivery.
Table 1. Clinical characteristics and demographics of patients with SGA and controls.
Plasma syndecan-1 concentration followed a nonlinear increase with gestational age in uncomplicated pregnancies
Maternal soluble plasma syndecan-1 concentrations (ng/mL) showed a nonlinear increase with gestational age in the group of uncomplicated pregnancies (R2 = 0.27, p < .001) ().
Figure 1. Soluble syndecan-1 concentrations (ng/mL) by gestational age (weeks) in control pregnancies. Soluble syndecan-1 concentrations followed a nonlinear increase with gestational age (R2 = 0.27, p < .001).
Plasma syndecan-1 was lower in pregnant women with an SGA fetus than in women with an AGA fetus
Soluble syndecan-1 was detected in the maternal plasma of all patients. Women with an SGA fetus had a lower mean plasma concentration of syndecan-1 than normal pregnant women [geometric mean (95% CI): 1113 (260–4764) ng/mL vs. 1527 (435–5363) ng/mL; p = .0001] (). Similar results were obtained after exclusion of patients with preexisting medical conditions (p = .0016).
Figure 2. Soluble syndecan-1 in normal pregnancies compared to pregnancies complicated by SGA. The mean plasma soluble syndecan-1 concentration was significantly lower in pregnancies complicated by an SGA fetus than in normal pregnancies [geometric mean (95% interval): 1113 (260–4764) ng/mL vs. 1527 (435–5363) ng/mL; p = .005]. SGA: small for gestational age.
![Figure 2. Soluble syndecan-1 in normal pregnancies compared to pregnancies complicated by SGA. The mean plasma soluble syndecan-1 concentration was significantly lower in pregnancies complicated by an SGA fetus than in normal pregnancies [geometric mean (95% interval): 1113 (260–4764) ng/mL vs. 1527 (435–5363) ng/mL; p = .005]. SGA: small for gestational age.](/cms/asset/5ffd0b7c-cbae-42d7-9aa8-7c5959998c5b/ijmf_a_2150074_f0002_c.jpg)
Only the group of women with an SGA fetus and abnormal Doppler velocimetry findings had a mean plasma syndecan-1 concentration significantly lower than that of controls
When results of Doppler velocimetry were considered, plasma syndecan-1 mean concentration was significantly lower in the group of women with an SGA fetus associated with abnormal uterine and umbilical artery Doppler velocimetry than in the group of women with an uncomplicated pregnancy [geometric mean (95% CI): 488 (139–1712) ng/mL vs. 1527 (435–5363) ng/mL; p = .00071; q = 0.0028] (). A trend toward lower mean plasma syndecan-1 concentrations was also noted for SGA with abnormal uterine but normal umbilical artery Doppler findings [geometric mean (95% CI): 1215 (230–6418) ng/mL vs 1527 (435–5363) ng/mL; p = .0505; q = 0.067] (). No significant difference was found in the mean plasma syndecan-1 concentration of women with an SGA fetus and normal Doppler findings compared to controls (q = 0.272). There was an inverse relationship between the plasma syndecan-1 concentration and the umbilical artery PI (r = −0.5; p = .003) as well as the mean uterine artery RI (r = −0.4; p = .04).
Figure 3. Soluble syndecan-1 in normal pregnancies compared to pregnancies complicated by SGA with and without abnormal uterine and umbilical artery Doppler velocimetry. When results of Doppler velocimetry were considered, the plasma syndecan-1 mean concentration was significantly lower in the group of women with an SGA fetus associated with abnormal uterine and umbilical artery Doppler velocimetry than in the group of women with an uncomplicated pregnancy [geometric mean (95% CI): 488 (139–1712) ng/mL vs. 1527 (435–5363) ng/mL; p = .00071; q = 0.0028]. A trend toward lower mean plasma syndecan-1 concentrations was also noted for SGA with abnormal uterine but normal umbilical artery Doppler findings, though not statistically significant after adjustment [geometric mean (95% CI): 1215 (230–6418) ng/mL vs 1527 (435–5363) ng/mL; p = .0505; q = 0.067]. No significant difference was found in the mean plasma syndecan-1 concentration of women with an SGA fetus and normal Doppler findings compared to controls (q = 0.272). CI: confidence interval; SGA: small for gestational age; UA: umbilical artery; UT: uterine artery.
![Figure 3. Soluble syndecan-1 in normal pregnancies compared to pregnancies complicated by SGA with and without abnormal uterine and umbilical artery Doppler velocimetry. When results of Doppler velocimetry were considered, the plasma syndecan-1 mean concentration was significantly lower in the group of women with an SGA fetus associated with abnormal uterine and umbilical artery Doppler velocimetry than in the group of women with an uncomplicated pregnancy [geometric mean (95% CI): 488 (139–1712) ng/mL vs. 1527 (435–5363) ng/mL; p = .00071; q = 0.0028]. A trend toward lower mean plasma syndecan-1 concentrations was also noted for SGA with abnormal uterine but normal umbilical artery Doppler findings, though not statistically significant after adjustment [geometric mean (95% CI): 1215 (230–6418) ng/mL vs 1527 (435–5363) ng/mL; p = .0505; q = 0.067]. No significant difference was found in the mean plasma syndecan-1 concentration of women with an SGA fetus and normal Doppler findings compared to controls (q = 0.272). CI: confidence interval; SGA: small for gestational age; UA: umbilical artery; UT: uterine artery.](/cms/asset/968a8276-1492-44a0-861f-9d35c43e07f9/ijmf_a_2150074_f0003_c.jpg)
Among women with an SGA fetus, the group with abnormal umbilical and uterine artery Doppler findings had the lower mean plasma syndecan-1 concentration
When pregnancies complicated with an SGA fetus were considered, the group of women with associated uterine and umbilical artery Doppler abnormalities had a significantly lower mean plasma syndecan-1 concentration than that of women without Doppler abnormalities [geometric mean (95% CI): 488 (139–1712) vs. 1521 (451–5126) ng/mL; p = .02; q = 0.04] ().
Syndecan-1 plasma concentrations identify SGA fetuses with abnormal umbilical artery Doppler velocimetry
A ROC analysis was performed to evaluate the performance of plasma syndecan-1 concentration in the identification of women with an SGA fetus with abnormal umbilical artery Doppler velocimetry in the study population. A plasma syndecan-1 concentration ≤ 850 ng/mL had a sensitivity of 80% (8/10), a specificity of 82% (132/161), a positive likelihood ratio of 4.4, and a negative likelihood ratio of 0.24 for the identification of a mother with an SGA fetus who had abnormal umbilical artery Doppler velocimetry (area under the ROC curve [AUC] 0.83; p < .001) ().
Figure 4. Receiver Operating Characteristic (ROC) curve to assess the diagnostic performance of plasma syndecan-1 concentration for the identification of women with an SGA fetus who had abnormal umbilical artery Doppler velocimetry in the study population. A plasma syndecan-1 concentration of 850 ng/mL or less had a sensitivity of 80% (8/10), a specificity of 82% (132/161), a likelihood ratio of a positive test of 4.4, and a likelihood ratio of a negative test of 0.24 (n = 171; area under the ROC curve 0.83; p < .001). SGA: small for gestational age.
Discussion
Principal findings
(1) Plasma syndecan-1 concentration followed a nonlinear increase with gestational age in uncomplicated pregnancies (R2 = 0.27, p < .001); (2) women with pregnancies complicated with an SGA fetus had a significantly lower mean plasma concentration of syndecan-1 than those with an AGA fetus (p = .005); (3) this difference can be attributed to FGR, as the mean plasma syndecan-1 concentration was significantly lower only in the group of women with an SGA fetus who had abnormal umbilical and uterine artery Doppler velocimetry compared to controls (p = .00071; q = 0.0028). A non-significant trend toward lower syndecan-1 concentrations was also noted for SGA with abnormal uterine but normal umbilical artery Doppler velocimetry (p = .0505; q = 0.067); 4) among women with an SGA fetus, those with abnormal umbilical and uterine artery Doppler findings had a significantly lower mean plasma syndecan-1 concentration than women with normal Doppler velocimetry (p = .02; q = 0.04); 5) an inverse relationship was found between the mean maternal plasma syndecan-1 concentration and the umbilical artery PI (r = −0.5; p = .003); and 6) a plasma syndecan-1 concentration ≤ 850 ng/mL had a positive likelihood ratio of 4.4 and a negative likelihood ratio of 0.24 for the identification of a mother with an SGA fetus who had abnormal umbilical artery Doppler velocimetry (AUC 0.83; p < .001).
Results in the context of what is known
Syndecan-1 in normal pregnancy
A growing body of evidence suggests that placental syndecan-1 plays an important role in normal pregnancy where it seems to be involved in implantation [Citation76], cell migration and proliferation [Citation39], and fetal-maternal inter-communication [Citation40]. Syndecan-1 also modulates the effects of multiple growth factors, e.g. angiogenic factors such as vascular endothelial growth factor (VEGF) [Citation76–80]. Plasma syndecan-1 concentrations have been reported to increase throughout pregnancy [Citation38,Citation66]. Gandley et al. evaluated maternal plasma syndecan-1 concentrations across uncomplicated pregnancies and found that plasma syndecan-1 starts to increase in early pregnancy, reaches a peak at term, and decreases within 24–48 h postpartum [Citation81]. The rapid drop in concentration after delivery has been interpreted as indicating that the placenta is a major source of syndecan-1 in maternal plasma [Citation38,Citation62,Citation81]. Studies investigating syndecan-1 immunostaining of placentas at different gestational ages showed no differences in the expression of syndecan-1 on the villous surface throughout gestation [Citation38,Citation41,Citation63,Citation82]. Syndecan-1 mRNA expression has been reported to be increased in BeWo cells exposed to forskolin, a culture model that simulates the process of trophoblast differentiation. This model provides evidence for a possible role of syndecan-1 in syncytialization of cytotrophoblasts [Citation38]. A possible explanation for the increase in plasma syndecan-1 concentrations during pregnancy, given the absence of changes in syndecan-1 expression on the surface of the villi as reported from immunostaining findings, is the increase in placental size, thus the release of syndecan-1 into the maternal circulation.
Syndecan-1 in complications of pregnancy
Altered placental syndecan-1 expression has been reported in pregnancies complicated by preeclampsia [Citation38,Citation63,Citation81–84] and HELLP syndrome [Citation38] and in a subset of patients with FGR [Citation84,Citation85]. The heterogeneity of the reported results can be attributed to the differences in the applied methodologies as well as to the heterogeneity of these syndromes [Citation86–88].
Circulating syndecan-1 has been evaluated in patients with preeclampsia. Several studies showed that plasma syndecan-1 concentrations are lower in patients with preeclampsia compared to normal pregnancies [Citation38,Citation81,Citation89–91]. Szabo et al. [Citation38] proposed this may be due to a defective syncytiotrophoblast transport of syndecan-1, possibly associated with an altered network of the syncytiotrophoblast’s cytoskeletal proteins reported in this syndrome [Citation92]. The finding that plasma syndecan-1 concentrations are lower in women with preeclampsia has been therefore attributed to a placental dysfunction rather than to endothelial damage. Recently, pregnant women with a growth-restricted fetus have also been reported to have lower plasma syndecan-1 concentrations than controls [Citation68,Citation69]. Collectively, the available evidence seems to support a role for syndecan-1 in various diseases of pregnancy, and some authors proposed that placental syndecan-1 in early gestation may be predictive of pregnancy outcomes [Citation93].
Plasma syndecan-1 concentration followed a nonlinear increase with gestational age in uncomplicated pregnancies
In this study, we found that maternal plasma syndecan-1 concentrations increased in a nonlinear fashion with gestational age in the group of uncomplicated pregnancies (R2 = 0.27, p < .001) (). This finding is consistent with the results of previous studies that showed a similar trend in plasma syndecan-1 concentrations throughout pregnancy [Citation38,Citation66,Citation81].
Plasma syndecan-1 is lower in pregnant women with SGA fetuses than in women with AGA fetuses
In the present study, plasma syndecan-1 concentrations were lower in patients with an SGA fetus than in normal pregnant women (). This finding is in agreement with the results reported by two previous studies published by Tong et al. in which maternal plasma syndecan-1 concentrations were lower in women with an SGA fetus at the time of diagnosis and, importantly, prior to the diagnosis, compared to women with normal pregnancy outcomes [Citation68,Citation69]. Moreover, circulating syndecan-1 concentrations were significantly correlated with birth weight centiles and placental weight [Citation68]. Interestingly, Garcha et al. [Citation68] reported that neither protein nor mRNA expression of syndecan-1 was altered in the placenta of patients who delivered an SGA neonate. However, the study by Chui et al. found that the expression of syndecan-1 mRNA and protein was significantly lower in the placenta of mothers with FGR fetuses than in those of controls [Citation85]. Relevant to these findings, in vitro experiments showed that exposure of primary cytotrophoblasts to hypoxic conditions (1% oxygen) decreased the secretion of syndecan-1 into the culture medium, an effect thought to be regulated by matrix metalloproteinases, which have been implicated in the cleavage of syndecan-1 from the syncytiotrophoblast. Thus, the low plasma syndecan-1 concentrations observed in mothers with an SGA fetus might be a consequence of hypoxic stress on the trophoblasts, interfering with the cleavage process of syndecan-1. Lastly, the same investigators reported that silencing syndecan-1 expression with siRNA determined a decrease in trophoblast proliferation [Citation68].
Maternal plasma syndecan-1 represents a biomarker for the identification of growth-restricted fetuses
The present study is the first to evaluate maternal plasma concentrations of syndecan-1 in pregnancies with an SGA fetus and to examine the relationship between syndecan-1 and Doppler velocimetry findings in umbilical and uterine arteries. Doppler velocimetry of the umbilical artery examines the impedance to blood flow in the placenta, and it has been used to assess placental disease [Citation94–97]. Deterioration of umbilical artery blood flow is associated with an abnormal biophysical profile [Citation98,Citation99], umbilical acidemia in cordocentesis [Citation99–103], and fetal vascular lesions of malperfusion in placental pathology [Citation94,Citation95,Citation104–110]. Abnormal Doppler velocimetry of the uterine artery is thought to reflect high impedance to uterine blood flow, as a consequence of failure of physiologic transformation of spiral arteries, which can lead to reduced uteroplacental perfusion [Citation105,Citation106,Citation111–114]. In 2016, a Delphi consensus of experts identified the alterations in umbilical or uterine artery Doppler velocimetry as contributory criteria to be applied in the differential diagnosis of SGA fetuses with EFW <10th percentile from fetal growth-restricted fetuses [Citation22]. The importance of distinguishing between an SGA fetus and an FGR fetus relies on the higher risk of abnormal perinatal outcome associated with FGR compared to SGA, which may include a large number of constitutionally small but healthy fetuses [Citation19–21].
Our findings showed that mothers with an SGA neonate with abnormal umbilical and uterine artery Doppler velocimetry had lower plasma concentrations of syndecan-1 compared to those with an AGA fetus (). We also found that there was a significantly lower mean plasma concentration of syndecan-1 in women with an SGA fetus who had abnormal umbilical and uterine artery Doppler velocimetry compared to women with an SGA fetus and normal Doppler findings (p = .02; q = 0.04). Among patients with SGA, those with an abnormal umbilical and uterine artery Doppler velocimetry had the lowest syndecan-1 concentration (). A trend toward a lower mean plasma concentration of syndecan-1 was also found in women with an SGA fetus and abnormal uterine artery Doppler findings only (with normal umbilical Doppler velocimetry) compared to uncomplicated pregnancies, though not statistically significant after adjustment (p = .0505; q = 0.067) (). We did not analyze the group of women with abnormal umbilical artery findings only, given that this represents an uncommon clinical scenario in FGR due to placental insufficiency and that only two patients with these characteristics were included in our study. Since uterine artery Doppler velocimetry is thought to reflect the degree of failure of physiologic transformation of the spiral arteries, syndecan-1 concentration in maternal plasma can also be a biomarker of shallow placentation [Citation25]. The relationship between plasma syndecan-1 concentrations and other placental lesions (i.e. chronic inflammatory lesions) observed in a subset of pregnancies with FGR remains to be determined.
Taken together, these results suggest that syndecan-1 may reflect placental disease, thus giving value to its possible role as a biomarker for FGR [Citation68]. In our study, a plasma syndecan-1 concentration ≤ 850 ng/mL enabled the identification of mothers with an SGA fetus who had abnormal umbilical artery Doppler velocimetry among the study population (AUC 0.83; p < .001). The accuracy, however, was low and unlikely to justify the implementation of syndecan-1 as a sole biomarker for this condition.
The diagnosis, surveillance, and time of delivery of fetuses with suspected FGR are major issues in obstetrics [Citation1,Citation3,Citation115–120]. There is a growing interest in finding additional imaging modalities or placental biomarkers able to reflect the presence of placental insufficiency and underperfusion and to improve the detection rate of growth-restricted fetuses [Citation68,Citation121–126]. Proposed candidates are proteins highly expressed in the placenta relative to other tissues such as serine peptidase inhibitor Kunitz type-1 (SPINT1) and growth differentiation factor-15, both previously investigated in the prediction of FGR [Citation69]. The results of this study provide further evidence for a possible role of plasma syndecan-1 in the early identification of fetuses with restricted growth during pregnancy.
Strengths and limitations
This is the first study in which maternal plasma soluble syndecan-1 concentrations have been correlated with umbilical and uterine artery Doppler velocimetry findings in pregnancies complicated with an SGA fetus. Integration of these results with placental findings and neonatal follow-up would add strength to our study. The findings that 80% of patients with an SGA fetus enrolled in this study had an EFW below the 5th percentile for gestational age may reflect our clinical setting and research operation at that time. As a tertiary referral center with a level-three neonatal intensive care unit, our hospital received transfer of care for several patients with early-onset SGA from local and near by regional hospitals. Moreover, patients with a more severe disease were more likely to be sent for ultrasound examinations and diagnosed with SGA due to size discrepancy from dates. We did not perform an ultrasound examination in every patient to screen for SGA. Additionally, the patients who were diagnosed with more severe FGR may have been more inclined to participate in the research study than those with a lesser degree of disease.
Conclusion
Low maternal plasma syndecan-1 may reflect placental diseases and this protein could be a biomarker for fetal growth restriction. However, as a sole biomarker for this condition, its accuracy is low.
Disclosure statement
No potential conflict of interest was reported by the author(s).
Additional information
Funding
References
- Lees CC, Romero R, Stampalija T, et al. Clinical opinion: the diagnosis and management of suspected fetal growth restriction: an evidence-based approach. Am J Obstet Gynecol. 2022;226(3):366–378.
- Baschat AA, Galan HL, Lee W, et al. The role of the fetal biophysical profile in the management of fetal growth restriction. Am J Obstet Gynecol. 2022;226(4):475–486.
- Deter RL, Lee W, Yeo L, et al. Individualized growth assessment: conceptual framework and practical implementation for the evaluation of fetal growth and neonatal growth outcome. Am J Obstet Gynecol. 2018;218(2s):S656–s678.
- Pacora P, Romero R, Jung E, et al. Reduced fetal growth velocity precedes antepartum fetal death. Ultrasound Obstet Gynecol. 2021;57(6):942–952.
- Lees C, Marlow N, Arabin B, et al. Perinatal morbidity and mortality in early-onset fetal growth restriction: cohort outcomes of the trial of randomized umbilical and fetal flow in Europe (TRUFFLE). Ultrasound Obstet Gynecol. 2013;42(4):400–408.
- Gardosi J, Francis A. Adverse pregnancy outcome and association with small for gestational age birthweight by customized and population-based percentiles. Am J Obstet Gynecol. 2009;201(1):28.e1-8–28.e8.
- Walker D-M, Marlow N, Upstone L, et al. The growth restriction intervention trial: long-term outcomes in a randomized trial of timing of delivery in fetal growth restriction. Am J Obstet Gynecol. 2011;204(1):34.e1-9–34.e9.
- Barker DJP, Osmond C, Forsén TJ, et al. Trajectories of growth among children who have coronary events as adults. N Engl J Med. 2005;353(17):1802–1809.
- Kajantie E, Osmond C, Barker DJP, et al. Size at birth as a predictor of mortality in adulthood: a follow-up of 350 000 person-years. Int J Epidemiol. 2005;34(3):655–663.
- Skilton MR, Evans N, Griffiths KA, et al. Aortic wall thickness in newborns with intrauterine growth restriction. Lancet. 2005;365(9469):1484–1486.
- Crispi F, Miranda J, Gratacós E. Long-term cardiovascular consequences of fetal growth restriction: biology, clinical implications, and opportunities for prevention of adult disease. Am J Obstet Gynecol. 2018;218(2s):S869–s879.
- Gluckman PD, Hanson MA, Cooper C, et al. Effect of in utero and early-life conditions on adult health and disease. N Engl J Med. 2008;359(1):61–73.
- Deter RL, Lee W, Kingdom J, et al. Second trimester growth velocities: assessment of fetal growth potential in SGA singletons. J Matern Fetal Neonatal Med. 2019;32(6):939–946.
- Platz E, Newman R. Diagnosis of IUGR: traditional biometry. Semin Perinatol. 2008;32(3):140–147.
- Grantz KL, Kim S, Grobman WA, et al. Fetal growth velocity: the NICHD fetal growth studies. Am J Obstet Gynecol. 2018;219(3):285.e1-285–e36.
- Chatzakis C, Papaioannou G-K, Eleftheriades M, et al. Perinatal outcome of appropriate-weight fetuses with decelerating growth. J Matern Fetal Neonatal Med. 2021;34(20):3362–3369.
- McCowan LM, Figueras F, Anderson NH. Evidence-based national guidelines for the management of suspected fetal growth restriction: comparison, consensus, and controversy. Am J Obstet Gynecol. 2018;218(2s):S855–s868.
- Hiersch L, Melamed N. Fetal growth velocity and body proportion in the assessment of growth. Am J Obstet Gynecol. 2018;218(2s):S700–S711.e1.
- Unterscheider J, Daly S, Geary MP, et al. Optimizing the definition of intrauterine growth restriction: the multicenter prospective Porto study. Am J Obstet Gynecol. 2013;208(4):290.e1-6–290.e6.
- Figueras F, Gratacós E. Update on the diagnosis and classification of fetal growth restriction and proposal of a stage-based management protocol. Fetal Diagn Ther. 2014;36(2):86–98.
- Ananth CV, Vintzileos AM. Distinguishing pathological from constitutional small for gestational age births in population-based studies. Early Hum Dev. 2009;85(10):653–658.
- Gordijn SJ, Beune IM, Thilaganathan B, et al. Consensus definition of fetal growth restriction: a Delphi procedure. Ultrasound Obstet Gynecol. 2016;48(3):333–339.
- Lees CC, Stampalija T, Baschat A, et al. ISUOG practice guidelines: diagnosis and management of small-for-gestational-age fetus and fetal growth restriction. Ultrasound Obstet Gynecol. 2020;56(2):298–312.
- Fleischer A, Schulman H, Farmakides G, et al. Umbilical artery velocity waveforms and intrauterine growth retardation. Am J Obstet Gynecol. 1985;151(4):502–505.
- Brosens I, Pijnenborg R, Vercruysse L, et al. The “great obstetrical syndromes” are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011;204(3):193–201.
- Trudinger BJ, Giles WB, Cook CM. Flow velocity waveforms in the maternal uteroplacental and fetal umbilical placental circulations. Am J Obstet Gynecol. 1985;152(2):155–163.
- Alfirevic Z, Stampalija T, Gyte GM. Fetal and umbilical Doppler ultrasound in high-risk pregnancies. Cochrane Database Syst Rev. 2013;2013(11):CD007529.
- Baschat AA, Cosmi E, Bilardo CM, et al. Predictors of neonatal outcome in early-onset placental dysfunction. Obstet Gynecol. 2007;109(2 Pt 1):253–261.
- Ferrazzi E, Bozzo M, Rigano S, et al. Temporal sequence of abnormal Doppler changes in the peripheral and central circulatory systems of the severely growth-restricted fetus. Ultrasound Obstet Gynecol. 2002;19(2):140–146.
- Tarbell JM, Cancel LM. The glycocalyx and its significance in human medicine. J Intern Med. 2016;280(1):97–113.
- Reitsma S, Slaaf DW, Vink H, et al. The endothelial glycocalyx: composition, functions, and visualization. Pflugers Arch. 2007;454(3):345–359.
- Pillinger NL, Kam P. Endothelial glycocalyx: basic science and clinical implications. Anaesth Intensive Care. 2017;45(3):295–307.
- Mertens G, Cassiman JJ, Van den Berghe H, et al. Cell surface heparan sulfate proteoglycans from human vascular endothelial cells. Core protein characterization and antithrombin III binding properties. J Biol Chem. 1992;267(28):20435–20443.
- Bernfield M, Götte M, Park PW, et al. Functions of cell surface heparan sulfate proteoglycans. Annu Rev Biochem. 1999;68:729–777.
- Villalba N, Baby S, Yuan SY. The endothelial glycocalyx as a Double-Edged sword in microvascular homeostasis and pathogenesis. Front Cell Dev Biol. 2021;9:711003.
- Bode L, Murch S, Freeze HH. Heparan sulfate plays a central role in a dynamic in vitro model of protein-losing enteropathy. J Biol Chem. 2006;281(12):7809–7815.
- Bode L, Eklund EA, Murch S, et al. Heparan sulfate depletion amplifies TNF-alpha-induced protein leakage in an in vitro model of protein-losing enteropathy. Am J Physiol Gastrointest Liver Physiol. 2005;288(5):G1015–23.
- Szabo S, Xu Y, Romero R, et al. Changes of placental syndecan-1 expression in preeclampsia and HELLP syndrome. Virchows Arch. 2013;463(3):445–458.
- Crescimanno C, Marzioni D, Paradinas FJ, et al. Expression pattern alterations of syndecans and glypican-1 in normal and pathological trophoblast. J Pathol. 1999;189(4):600–608.
- Lorenzi T, Turi A, Crescimanno C, et al. Syndecan expressions in the human amnion and chorionic plate. Eur J Histochem. 2010;54(4):e42.
- Jokimaa V, Inki P, Kujari H, et al. Expression of syndecan-1 in human placenta and decidua. Placenta. 1998;19(2-3):157–163.
- Moore KH, Murphy HA, Chapman H, et al. Syncytialization alters the extracellular matrix and barrier function of placental trophoblasts. Am J Physiol Cell Physiol. 2021;321(4):C694–C703.
- Couchman JR. Syndecans: proteoglycan regulators of cell-surface microdomains? Nat Rev Mol Cell Biol. 2003;4(12):926–937.
- Yoneda A, Couchman JR. Regulation of cytoskeletal organization by syndecan transmembrane proteoglycans. Matrix Biol. 2003;22(1):25–33.
- Hahn RG, Patel V, Dull RO. Human glycocalyx shedding: systematic review and critical appraisal. Acta Anaesthesiol Scand. 2021;65(5):590–606.
- Dogné S, Flamion B, Caron N. Endothelial glycocalyx as a shield against diabetic vascular complications: involvement of hyaluronan and hyaluronidases. Arterioscler Thromb Vasc Biol. 2018;38(7):1427–1439.
- Yanagishita M, Hascall VC. Cell surface heparan sulfate proteoglycans. J Biol Chem. 1992;267(14):9451–9454.
- Kim CW, Goldberger OA, Gallo RL, et al. Members of the syndecan family of heparan sulfate proteoglycans are expressed in distinct cell-, tissue-, and development-specific patterns. Mol Biol Cell. 1994;5(7):797–805.
- Rehm M, Bruegger D, Christ F, et al. Shedding of the endothelial glycocalyx in patients undergoing major vascular surgery with global and regional ischemia. Circulation. 2007;116(17):1896–1906.
- Ushiyama A, Kataoka H, Iijima T. Glycocalyx and its involvement in clinical pathophysiologies. J Intensive Care. 2016;4(1):59.
- Johansson PI, Stensballe J, Rasmussen LS, et al. A high admission syndecan-1 level, a marker of endothelial glycocalyx degradation, is associated with inflammation, protein C depletion, fibrinolysis, and increased mortality in trauma patients. Ann Surg. 2011;254(2):194–200.
- Gonzalez Rodriguez E, Ostrowski SR, Cardenas JC, et al. Syndecan-1: a quantitative marker for the endotheliopathy of trauma. J Am Coll Surg. 2017;225(3):419–427.
- Nelson A, Berkestedt I, Schmidtchen A, et al. Increased levels of glycosaminoglycans during septic shock: relation to mortality and the antibacterial actions of plasma. Shock. 2008;30(6):623–627.
- Suzuki K, Okada H, Sumi K, et al. Serum syndecan-1 reflects organ dysfunction in critically ill patients. Sci Rep. 2021;11(1):8864.
- Puskarich MA, Cornelius DC, Tharp J, et al. Plasma syndecan-1 levels identify a cohort of patients with severe sepsis at high risk for intubation after large-volume intravenous fluid resuscitation. J Crit Care. 2016;36:125–129.
- Piotti A, Novelli D, Meessen JMTA, et al. Endothelial damage in septic shock patients as evidenced by circulating syndecan-1, sphingosine-1-phosphate and soluble VE-cadherin: a substudy of ALBIOS. Crit Care. 2021;25(1):113.
- Padberg J-S, Wiesinger A, di Marco GS, et al. Damage of the endothelial glycocalyx in chronic kidney disease. Atherosclerosis. 2014;234(2):335–343.
- Chen X, Geng X, Jin S, et al. The association of syndecan-1, hypercoagulable state and thrombosis and in patients with nephrotic syndrome. Clin Appl Thromb Hemost. 2021;27:10760296211010256.
- Kitagawa Y, Kawamura I, Suzuki K, et al. Serum syndecan-1 concentration in hospitalized patients with heart failure may predict readmission-free survival. PLoS One. 2021;16(12):e0260350.
- Miranda CH, de Carvalho Borges M, Schmidt A, et al. Evaluation of the endothelial glycocalyx damage in patients with acute coronary syndrome. Atherosclerosis. 2016;247:184–188.
- Bell JD, Rhind SG, Di Battista AP, et al. Biomarkers of glycocalyx injury are associated with delayed cerebral ischemia following aneurysmal subarachnoid hemorrhage: a case series supporting a new hypothesis. Neurocrit Care. 2017;26(3):339–347.
- Oravecz O, Balogh A, Romero R, et al. Proteoglycans: systems-Level insight into their expression in healthy and diseased placentas. IJMS. 2022;23(10):5798.
- Heyer-Chauhan N, Ovbude IJ, Hills AA, et al. Placental syndecan-1 and sulphated glycosaminoglycans are decreased in preeclampsia. J Perinat Med. 2014;42(3):329–338.
- Inki P, Jalkanen M. Regulation of cell morphology and growth by syndecan-1: altered expression in malignancy. Cytoskeleton. 1996;3:305–324.
- Baston-Buest DM, Altergot-Ahmad O, Pour SJ, et al. Syndecan-1 acts as an important regulator of CXCL1 expression and cellular interaction of human endometrial stromal and trophoblast cells. Mediators Inflamm. 2017. 2017;2017:8379256.
- Hofmann-Kiefer KF, Knabl J, Martinoff N, et al. Increased serum concentrations of circulating glycocalyx components in HELLP syndrome compared to healthy pregnancy: an observational study. Reprod Sci. 2013;20(3):318–325.
- Greeley ET, Rochelson B, Krantz DA, et al. Evaluation of syndecan-1 as a novel biomarker for adverse pregnancy outcomes. Reprod Sci. 2020;27(1):355–363.
- Garcha D, Walker SP, MacDonald TM, et al. Circulating syndecan-1 is reduced in pregnancies with poor fetal growth and its secretion regulated by matrix metalloproteinases and the mitochondria. Sci Rep. 2021;11(1):16595.
- Kaitu’u-Lino TJ, MacDonald TM, Cannon P, et al. Circulating SPINT1 is a biomarker of pregnancies with poor placental function and fetal growth restriction. Nat Commun. 2020;11(1):2411.
- Hadlock FP, Harrist RB, Sharman RS, et al. Estimation of fetal weight with the use of head, body, and femur measurements–a prospective study. Am J Obstet Gynecol. 1985;151(3):333–337.
- Alexander GR, Himes JH, Kaufman RB, et al. A United States national reference for fetal growth. Obstet Gynecol. 1996;87(2):163–168.
- ACOG Committee on Obstetric Practice. ACOG practice bulletin. Diagnosis and management of preeclampsia and eclampsia. Obstet Gynecol. 2002;99(1):159–167.
- Arduini D, Rizzo G. Normal values of pulsatility index from fetal vessels: a cross-sectional study on 1556 healthy fetuses. J Perinat Med. 1990;18(3):165–172.
- Trudinger BJ, Cook CM, Giles WB, et al. Fetal umbilical artery velocity waveforms and subsequent neonatal outcome. Br J Obstet Gynaecol. 1991;98(4):378–384.
- Kurmanavicius J, Florio I, Wisser J, et al. Reference resistance indices of the umbilical, fetal middle cerebral and uterine arteries at 24-42 weeks of gestation. Ultrasound Obstet Gynecol. 1997;10(2):112–120.
- Baston-Büst DM, Götte M, Janni W, et al. Syndecan-1 knock-down in decidualized human endometrial stromal cells leads to significant changes in cytokine and angiogenic factor expression patterns. Reprod Biol Endocrinol. 2010;8:133.
- Ferretti C, Bruni L, Dangles-Marie V, et al. Molecular circuits shared by placental and cancer cells, and their implications in the proliferative, invasive and migratory capacities of trophoblasts. Hum Reprod Update. 2007;13(2):121–141.
- Larrain J, et al. Syndecan-1 expression is down-regulated during myoblast terminal differentiation. Modulation by growth factors and retinoic acid. J Biol Chem. 1997;272(29):18418–18424.
- Bonneh-Barkay D, Shlissel M, Berman B, et al. Identification of glypican as a dual modulator of the biological activity of fibroblast growth factors. J Biol Chem. 1997;272(19):12415–12421.
- Bernfield M, Sanderson RD. Syndecan, a developmentally regulated cell surface proteoglycan that binds extracellular matrix and growth factors. Philos Trans R Soc Lond B Biol Sci. 1990;327(1239):171–186.
- Gandley RE, Althouse A, Jeyabalan A, et al. Low soluble syndecan-1 precedes preeclampsia. PLoS One. 2016;11(6):e0157608.
- Jokimaa VI, Kujari HP, Ekholm EM, et al. Placental expression of syndecan 1 is diminished in preeclampsia. Am J Obstet Gynecol. 2000;183(6):1495–1498.
- Chui A, Murthi P, Brennecke SP, et al. The expression of placental proteoglycans in pre-eclampsia. Gynecol Obstet Invest. 2012;73(4):277–284.
- Ogawa M, Yanoma S, Nagashima Y, et al. Paradoxical discrepancy between the serum level and the placental intensity of PP5/TFPI-2 in preeclampsia and/or intrauterine growth restriction: possible interaction and correlation with glypican-3 hold the key. Placenta. 2007;28(2-3):224–232.
- Chui A, Zainuddin N, Rajaraman G, et al. Placental syndecan expression is altered in human idiopathic fetal growth restriction. Am J Pathol. 2012;180(2):693–702.
- Than NG, Vaisbuch E, Kim CJ, et al. Early-onset preeclampsia and HELLP syndrome: an overview. In Preedy VR, editors. Handbook of growth and growth monitoring in health and disease. Cham: Springer, 2012. p. 1867–1891.
- Ness RB, Roberts JM. Heterogeneous causes constituting the single syndrome of preeclampsia: a hypothesis and its implications. Am J Obstet Gynecol. 1996;175(5):1365–1370.
- von Dadelszen P, Magee LA, Roberts JM. Subclassification of preeclampsia. Hypertens Pregnancy. 2003;22(2):143–148.
- Kornacki J, Wirstlein P, Wender-Ozegowska E. Serum levels of soluble FMS-like tyrosine kinase 1 and endothelial glycocalyx components in early- and late-onset preeclampsia. J Matern Fetal Neonatal Med. 2022;35(25):7466–7470.
- Alici Davutoğlu E, Akkaya Firat A, Ozel A, et al. Evaluation of maternal serum hypoxia inducible factor-1α, progranulin and syndecan-1 levels in pregnancies with early- and late-onset preeclampsia. J Matern Fetal Neonatal Med. 2018;31(15):1976–1982.
- Kuessel L, Husslein H, Montanari E, et al. Dynamics of soluble syndecan-1 in maternal serum during and after pregnancies complicated by preeclampsia: a nested case control study. Clin Chem Lab Med. 2019;58(1):50–58.
- Riquelme G, Vallejos C, de Gregorio N, et al. Lipid rafts and cytoskeletal proteins in placental microvilli membranes from preeclamptic and IUGR pregnancies. J Membr Biol. 2011;241(3):127–140.
- Schmedt A, Götte M, Heinig J, et al. Evaluation of placental syndecan-1 expression in early pregnancy as a predictive fetal factor for pregnancy outcome. Prenat Diagn. 2012;32(2):131–137.
- Thompson RS, Trudinger BJ. Doppler waveform pulsatility index and resistance, pressure and flow in the umbilical placental circulation: an investigation using a mathematical model. Ultrasound Med Biol. 1990;16(5):449–458.
- Giles WB, Trudinger BJ, Baird PJ. Fetal umbilical artery flow velocity waveforms and placental resistance: pathological correlation. Br J Obstet Gynaecol. 1985;92(1):31–38.
- Spinillo A, Gardella B, Bariselli S, et al. Placental histopathological correlates of umbilical artery Doppler velocimetry in pregnancies complicated by fetal growth restriction. Prenat Diagn. 2012;32(13):1263–1272.
- Parra-Saavedra M, Crovetto F, Triunfo S, et al. Placental findings in late-onset SGA births without Doppler signs of placental insufficiency. Placenta. 2013;34(12):1136–1141.
- Baschat AA, Gembruch U, Harman CR. The sequence of changes in Doppler and biophysical parameters as severe fetal growth restriction worsens. Ultrasound Obstet Gynecol. 2001;18(6):571–577.
- Karsdorp VH, van Vugt JM, van Geijn HP, et al. Clinical significance of absent or reversed end diastolic velocity waveforms in umbilical artery. Lancet. 1994;344(8938):1664–1668.
- Bilardo CM, Nicolaides KH, Campbell S. Doppler measurements of fetal and uteroplacental circulations: relationship with umbilical venous blood gases measured at cordocentesis. Am J Obstet Gynecol. 1990;162(1):115–120.
- Yoon BH, Romero R, Roh CR, et al. Relationship between the fetal biophysical profile score, umbilical artery Doppler velocimetry, and fetal blood acid-base status determined by cordocentesis. Am J Obstet Gynecol. 1993;169(6):1586–1594.
- Nicolaides KH, Bilardo CM, Soothill PW, et al. Absence of end diastolic frequencies in umbilical artery: a sign of fetal hypoxia and acidosis. BMJ. 1988;297(6655):1026–1027.
- Hecher K, Campbell S, Doyle P, et al. Assessment of fetal compromise by Doppler ultrasound investigation of the fetal circulation. Arterial, intracardiac, and venous blood flow velocity studies. Circulation. 1995;91(1):129–138.
- Labarrere CA, Althabe OH. Inadequate maternal vascular response to placentation in pregnancies complicated by preeclampsia and by small-for-gestational-age infants. Br J Obstet Gynaecol. 1987;94(11):1113–1116.
- Mifsud W, Sebire NJ. Placental pathology in early-onset and late-onset fetal growth restriction. Fetal Diagn Ther. 2014;36(2):117–128.
- Burton GJ, Jauniaux E. Pathophysiology of placental-derived fetal growth restriction. Am J Obstet Gynecol. 2018;218(2s):S745–s761.
- Macara L, Kingdom JC, Kaufmann P, et al. Structural analysis of placental terminal villi from growth-restricted pregnancies with abnormal umbilical artery Doppler waveforms. Placenta. 1996;17(1):37–48.
- Jackson MR, Walsh AJ, Morrow RJ, et al. Reduced placental villous tree elaboration in small-for-gestational-age pregnancies: relationship with umbilical artery Doppler waveforms. Am J Obstet Gynecol. 1995;172(2 Pt 1):518–525.
- Hitschold T, Weiss E, Beck T, et al. Low target birth weight or growth retardation? Umbilical Doppler flow velocity waveforms and histometric analysis of fetoplacental vascular tree. Am J Obstet Gynecol. 1993;168(4):1260–1264.
- Jauniaux E, Jurkovic D, Campbell S, et al. Investigation of placental circulations by color Doppler ultrasonography. Am J Obstet Gynecol. 1991;164(2):486–488.
- Olofsson P, Laurini RN, Marsál K. A high uterine artery pulsatility index reflects a defective development of placental bed spiral arteries in pregnancies complicated by hypertension and fetal growth retardation. Eur J Obstet Gynecol Reprod Biol. 1993;49(3):161–168.
- Brosens I, Puttemans P, Benagiano G. Placental bed research: I. The placental bed: from spiral arteries remodeling to the great obstetrical syndromes. Am J Obstet Gynecol. 2019;221(5):437–456.
- Ferrazzi E, Bulfamante G, Mezzopane R, et al. Uterine Doppler velocimetry and placental hypoxic-ischemic lesion in pregnancies with fetal intrauterine growth restriction. Placenta. 1999;20(5-6):389–394.
- Lin S, Shimizu I, Suehara N, et al. Uterine artery Doppler velocimetry in relation to trophoblast migration into the myometrium of the placental bed. Obstet Gynecol. 1995;85(5 Pt 1):760–765.
- Romero R, Kingdom J, Deter R, et al. Fetal growth: evaluation and management. Am J Obstet Gynecol. 2018;218(2s):S608.
- Lees CC, Marlow N, van Wassenaer-Leemhuis A, et al. 2 Year neurodevelopmental and intermediate perinatal outcomes in infants with very preterm fetal growth restriction (TRUFFLE): a randomised trial. Lancet. 2015;385(9983):2162–2172.
- Hecher K, Bilardo CM, Stigter RH, et al. Monitoring of fetuses with intrauterine growth restriction: a longitudinal study. Ultrasound Obstet Gynecol. 2001;18(6):564–570.
- Romero R, Tarca AL. Fetal size standards to diagnose a small- or a large-for-gestational-age fetus. Am J Obstet Gynecol. 2018;218(2s):S605–s607.
- Gardosi J, Francis A, Turner S, et al. Customized growth charts: rationale, validation and clinical benefits. Am J Obstet Gynecol. 2018;218(2s):S609–s618.
- Figueras F, Caradeux J, Crispi F, et al. Diagnosis and surveillance of late-onset fetal growth restriction. Am J Obstet Gynecol. 2018;218(2s):S790–S802.e1.
- Ciobanu A, Rouvali A, Syngelaki A, et al. Prediction of small for gestational age neonates: screening by maternal factors, fetal biometry, and biomarkers at 35-37 weeks’ gestation. Am J Obstet Gynecol. 2019;220(5):486.e1–486.e11.
- Parra-Saavedra M, Simeone S, Triunfo S, et al. Correlation between histological signs of placental underperfusion and perinatal morbidity in late-onset small-for-gestational-age fetuses. Ultrasound Obstet Gynecol. 2015;45(2):149–155.
- Lesmes C, Gallo DM, Gonzalez R, et al. Prediction of small-for-gestational-age neonates: screening by maternal serum biochemical markers at 19-24 weeks. Ultrasound Obstet Gynecol. 2015;46(3):341–349.
- Poon LC, Lesmes C, Gallo DM, et al. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 19-24 weeks. Ultrasound Obstet Gynecol. 2015;46(4):437–445.
- Bakalis S, Peeva G, Gonzalez R, et al. Prediction of small-for-gestational-age neonates: screening by biophysical and biochemical markers at 30-34 weeks. Ultrasound Obstet Gynecol. 2015;46(4):446–451.
- Gaccioli F, Aye ILMH, Sovio U, et al. Screening for fetal growth restriction using fetal biometry combined with maternal biomarkers. Am J Obstet Gynecol. 2018;218(2s):S725–s737.